Falls in Older Adults with Multiple Myeloma.
Wildes TM et al. Eur J Haematol. 2017 Dec 14. doi: 10.1111/ejh.13009. [Epub ahead of print].

BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations From the Organizing Committee.
Holstein SA et al. Biol Blood Marrow Transplant. 2017 Dec 11. pii: S1083-8791(17)31678-6. doi: 10.1016/j.bbmt.2017.12.774. [Epub ahead of print].

Multiple Myeloma and Bone: The Fatal Interaction.
Marino S et al.Cold Spring Harb Perspect Med. 2017 Dec 11. pii: a031286. doi: 10.1101/cshperspect.a031286. [Epub ahead of print].

A clinical picture of pulmonary embolism revealing light-chain myeloma.
Belarj B et al. Clin Case Rep. 2017 Nov 2;5(12):2044-2046. doi: 10.1002/ccr3.1234. eCollection 2017 Dec.

Management of multiple myeloma in the relapsed/refractory patient.
Sonneveld P. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):508-517. doi: 10.1182/asheducation-2017.1.508.

Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies.
Kumar S. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):518-524. doi: 10.1182/asheducation-2017.1.518.

Management of multiple myeloma in the newly diagnosed patient.
Mateos MV et al. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):498-507. doi: 10.1182/asheducation-2017.1.498.

Fixed duration vs continuous therapy in multiple myeloma.
Ludwig H et al. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):212-222. doi: 10.1182/asheducation-2017.1.212.

Is molecular remission the goal of multiple myeloma therapy?Davies FE et al. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):205-211. doi: 10.1182/asheducation-2017.1.205.

Shall we treat smoldering multiple myeloma in the near future?Landgren O. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):194-204. doi: 10.1182/asheducation-2017.1.194.

Therapy sequencing strategies in multiple myeloma: who, what and why?
Costello C et al. Future Oncol. 2017 Dec 8. doi: 10.2217/fon-2017-0493. [Epub ahead of print].

Outcome and survival of myeloma patients diagnosed 2008-2015. Real world data on 4904 patients from the Swedish Myeloma Registry (SMR).
Blimark CH et al. Haematologica. 2017 Dec 7. pii: haematol.2017.178103. doi: 10.3324/haematol.2017.178103. [Epub ahead of print].

From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives.
Gay F et al. Haematologica. 2017 Dec 7. pii: haematol.2017.174573. doi: 10.3324/haematol.2017.174573. [Epub ahead of print].

MRD in multiple myeloma: more questions than answers?
Moreau P et al. Blood Cancer J. 2017 Dec 5;7(12):639. doi: 10.1038/s41408-017-0028-5.

A historical perspective on milestones in multiple myeloma research.
Ribatti D et al. Eur J Haematol. 2017 Dec 1. doi: 10.1111/ejh.13003. [Epub ahead of print].

Clinical pharmacokinetics of oral drugs in the treatment of multiple myeloma.
Morival C et al. Hematol Oncol. 2017 Nov 27. doi: 10.1002/hon.2485. [Epub ahead of print].

First targeted therapy in multiple myeloma.
Kortüm KM et al. Blood. 2017 Nov 30;130(22):2359-2360. doi: 10.1182/blood-2017-09-805341.

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.
Nijhof IS et al. Drugs. 2017 Nov 29. doi: 10.1007/s40265-017-0841-y. [Epub ahead of print].

Decision Aids: Assisting Patients With Multiple Myeloma and Caregivers With Treatment Decision Making.
Kojovic B et al. Clin J Oncol Nurs. 2017 Dec 1;21(6):660-664. doi: 10.1188/17.CJON.660-664.

Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States.
Jakubowiak AJ et al. Expert Rev Hematol. 2017 Dec;10(12):1107-1119. doi: 10.1080/17474086.2017.1391088.

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.
Sørrig R et al. PLoS One. 2017 Dec 7;12(12):e0188988. doi: 10.1371/journal.pone.0188988. eCollection 2017.

The therapeutic effect of modified Huangqi Guizhi Wuwu Tang for multiple myeloma: An 18-year follow-up case report.
Tian M et al. Medicine (Baltimore). 2017 Dec;96(49):e9074. doi: 10.1097/MD.0000000000009074.